|
 |
|
Inmedix holds the “use” patent on ropinirole and seeks a partner to develop, market, and sell ropinirole on a worldwide basis for the treatment of Fibromyalgia. Ropinirole is a second generation dopamine agonist and one of two discovered dopamine 2/3 receptor agonists commonly used to treat Parkinson’s disease and Restless Leg Syndrome. It has no effect on beta-adrenergic, serotonin, norepinepherine, muscarinic, opioid, GABA, dopamine (1,4,5), benzodiazepine or other CNS receptors. Because of its uniquely specific mechanism of action, important conclusions can be drawn from observation of its clinical effect in patients with fibromyalgia. Ropinirole was developed by GSK and FDA approved for treatment of Parkinson’s disease in 1997 and for restless leg Extensive published reports in clinical trails with ropinirole indicate that it is well tolerated even in a high-risk elderly population with Parkinson’s disease. In the Inmedix placebo controlled FMS trial, the primary adverse event was mild, transient nausea. Non-confidential Product Sheet for Ropinirole
Phase I Completed Investigational treatment of FMS with ropinirole was first reported in 2003 in the Journal of Clinical Rheumatology, and a pilot randomized, placebo controlled trial was reported at the annual meetings of the American College of Rheumatology and British Society for Rheumatology. Phase I results as published in Journal of Clinical Rheumatology Inmedix patent related to ropinirole US Patent Office number: US 6,277,875 b1 |
